Table 2.
Laboratory findings at second admission
| Urinalysis | BC | Serology | |||
| Pro. | (4 +) | T.Bil | 0.2 mg/dL | CRP | < 0.05 mg/dL |
| Glu. | (−) | AST | 28 IU/L | IgG | 649 mg/dL |
| Urobili. | (±) | ALT | 12 IU/L | IgA | 189 U/dL |
| Bil. | (−) | γ-GTP | 10 IU/L | IgM | 170 mg/dL |
| Ket. | (−) | ALP | 99 IU/L | CH50 | 5 U/dL |
| Occult blood | (2 +) | LDH | 247 IU/L | C3 | 3.6 mg/dL |
| Sed. | TP | 3.5 g/dL | C4 | 34 mg/dL | |
| RBC | 5–9/HPF | Alb | 1.3 g/dL | Anti-nuclear-Ab | × 1280 (homogeneous) |
| WBC | 5–9/HPF | CK | 135 IU/dL | Anti-dsDNAIgG | > 380 IU/mL |
| Casts | 100–999/HPF | BUN | 7.3 mg/dL | PR3-ANCA | < 0.5 U/mL |
| CBC | Cr | 0.65 mg/dL | MPO-ANCA | < 0.5 U/mL | |
| WBC | 2790/mL | Na | 144 mEq/dL | Anti-GBM-Ab | < 0.5 U/mL |
| RBC | 406 × 104/mL | K | 3.0 mEq/dL | Anti-CL-β2GP | < 1.3 U/mL |
| Hb | 9.1 g/dL | Cl | 108 mEq/dL | Anti-cardio-IgG | 7 U/mL |
| Hct | 30.2% | Ca | 7.2 mg/dL | HBs-Ag | (−) |
| MCV | 74.4% | P | 4.3 mg/dL | HCV-Ab | (−) |
| MCH | 22.4 pg | T.chol | 429 mg/dL | TPHA | (−) |
| MCHC | 30.1% | TG | 80 mg/dL | RPR | (−) |
| PLT | 23.9 × 104/mL | LDL-chol | 399 mg/dL | Lupus anticoagulant | 4.5 s |
| Urinary protein excretion | 16.6 g/day | ||||
Abnormal data have been underlined
Anti-nuclear-Ab antinuclear antibodies, Anti-dsDNAIgG anti-double stranded deoxyribonucleic acid-immunoglobulin G antibodies, PR3-ANCA proteinase3-antineutrophil cytoplasmic antibodies, MPO-ANCA myeloperoxidase-antineutrophil cytoplasmic antibodies, Anti-GBM-Ab anti-glomerular basement membrane antibodies, Anti-CL-β2GP anti-cardiolipin beta2 glycoprotein 1 antibodies, TPHA treponema pallidum hemagglutination test, RPR rapid plasma regain card agglutination test